Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 21;22(3):961-73.
doi: 10.3748/wjg.v22.i3.961.

Inflammatory bowel disease associated neoplasia: A surgeon's perspective

Azah A Althumairi  1 , Mark G Lazarev  1 , Susan L Gearhart  1
Affiliations
Review

Inflammatory bowel disease associated neoplasia: A surgeon's perspective

Azah A Althumairi et al. World J Gastroenterol. .

Abstract

Inflammatory bowel disease (IBD) is associated with increased risk of colorectal cancer (CRC). The risk is known to increase with longer duration of the disease, family history of CRC, and history of primary sclerosing cholangitis. The diagnosis of the neoplastic changes associated with IBD is difficult owing to the heterogeneous endoscopic appearance and inter-observer variability of the pathological diagnosis. Screening and surveillance guidelines have been established which aim for early detection of neoplasia. Several surgical options are available for the treatment of IBD-associated neoplasia. Patients' morbidities, risk factors for CRC, degree and the extent of neoplasia must be considered in choosing the surgical treatment. A multidisciplinary team including the surgeon, gastroenterologist, pathologist, and the patient who has a clear understanding of the nature of their disease is needed to optimize outcomes.

Keywords: Colectomy; Colorectal cancer; Dysplasia; Endoscopy; Inflammatory bowel disease; Surveillance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kudo criteria appearance.
See this image and copyright information in PMC

References

    1. Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res. 2011;4:53–61. - PMC - PubMed
    1. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378–389. - PMC - PubMed
    1. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727. - PubMed
    1. Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) 2014;1:3. - PMC - PubMed
    1. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102–1111.e2. - PubMed

MeSH terms

Substances